DecImmune Therapeutics Receives $1,749,999 Series A Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=74e35046-0462-4c73-869a-60e61886cd3d&Preview=1 -
Date
1/17/2013 -
Company Name
DecImmune Therapeutics -
Mailing Address
800 Huntington Ave. Boston, MA 02115 -
Company Description
The company operates as a drug development company focused on inflammation. -
Website
http://www.decimmune.com -
Transaction Type
Venture Equity -
Transaction Amount
$1,749,999 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. -
M&A Terms
-
Venture Investor
Undisclosed
